Want to see JNJ full AI Analyst Report?

Johnson & Johnson (JNJ) Price & Analysis

28,375 Followers

JNJ Stock Chart & Stats

$263.40

$4.13(1.59%)

At close: Jul 24 4:00 PM EDT

$263.40

$4.13(1.59%)

Day’s Range― - ―

52-Week Range$169.68 - $274.90

Previous CloseN/A

Volume6.35M

Average Volume (3M)8.54M

Market Cap

$617.78B

Enterprise Value$649.67K

Total Cash (Recent Filing)$20.76B

Total Debt (Recent Filing)$49.04B

Price to Earnings (P/E)29.6

Beta-0.02

Next Earnings

Oct 20, 2026

EPS Estimate

2.9

Next Dividend Ex-DateN/A

Dividend Yield2.04%

Share Statistics

EPS (TTM)8.65

Shares Outstanding2,409,898,700

10 Day Avg. Volume8,523,926

30 Day Avg. Volume8,542,877

Financial Highlights & Ratios

PEG Ratio0.21

Price to Book (P/B)6.18

Price to Sales (P/S)5.35

P/FCF Ratio25.59

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda<0.01

Forecast

1Y Price Target

$281.00

Price Target Upside6.68% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering17

EPS Forecast (FY)11.62

Revenue Forecast (FY)$101.27B

Bulls Say, Bears Say

Bulls Say

High Profitability And Margin SustainabilityJohnson & Johnson’s trailing‑12‑month gross, operating and net margins are very strong, reflecting durable pricing power, efficient cost structure, and scale across pharmaceuticals and MedTech. High core margins support sustained R&D investment, product launches, and long‑term cash returns to stakeholders.

Robust Cash Generation And Conservative LeverageConsistent free cash flow conversion and low relative debt create meaningful financial flexibility. A large cash balance plus modest leverage supports M&A, pipeline funding, and shareholder programs without relying on high recurring borrowing, reducing financial risk over the medium term.

Diversified High‑Growth Product Mix And Pipeline/M&ABroadly diversified growth across multiple recent launches and established brands reduces single‑product dependence. Active pipeline catalysts plus targeted M&A (e.g., Firefly) enhance oncology and novel modality capabilities, improving medium‑term revenue resilience and strategic positioning.

Bears Say

STELARA Biosimilar Impact And Legacy Product DeclineA >50% decline in a legacy biologic demonstrates how biosimilar entry and therapeutic class shifts can rapidly erode material revenue streams. Replacing that cash flow requires successful new launches and sustained uptake, creating revenue volatility over multiple quarters.

MedTech Procedure Sensitivity And Regional Inventory PressureMedTech revenue is exposed to procedure volumes, physician preference and regional inventory cycles. Slower cardiology demand, selectivity after neutral trials, and China inventory distortions can depress growth for an extended period until procedure volumes, trial readouts and inventory normalization occur.

Legal/Liability And Near‑Term Earnings Dilution From DealsLarge contingent litigation exposure and recent M&A accounting charges create near‑term cash and EPS pressure. Settlement obligations and in‑process R&D write‑offs reduce free cash available for strategic uses and introduce execution and timing risk for returning normalized earnings power.

Johnson & Johnson News

3 Best Vanguard ETFs to Build Passive Income in Retirement

Many investors focus on building a large retirement portfolio. However, the bigger challenge is turning those savings into...

4h ago

JNJ

Johnson & Johnson price target raised to $287 from $270 at Guggenheim

Guggenheim raised the firm’s price target on Johnson & Johnson to $287 from $270 and keeps a Buy...

11h ago

JNJ

3 ‘Strong Buy’ Dividend Aristocrat Stocks for Dependable Income, 8/5/26

For investors seeking dependable dividend income, International Business Machines ($IBM), Johnson & Johnson ($JNJ), and Coca-Cola ($KO) stand...

1d ago

IBM

Zymeworks price target raised to $51 from $46 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Zymeworks (ZYME) to $51 from $46 and keeps a Buy...

1d ago

JNJ

JAZZ

Johnson & Johnson announces Taubert to retire as EVP, Worldwide Chairman

Johnson & Johnson announced that Jennifer Taubert will retire from her position as Executive Vice President, EVP, Worldwide...

2d ago

JNJ

Broadcom Stock (AVGO) Falls as Goldman Sachs Removes It From the ‘Conviction List’

The bank sees the market rally broadening out beyond AI. ...

3d ago

DAL

Johnson & Johnson price target raised to $282 from $272 at Wells Fargo

Wells Fargo raised the firm’s price target on Johnson & Johnson to $282 from $272 and keeps an...

3d ago

JNJ

Johnson & Johnson removed from US Conviction List at Goldman Sachs

Goldman Sachs analysts removed Johnson & Johnson from the firm’s US Conviction List as part of its monthly...

3d ago

JNJ

Johnson & Johnson’s head & neck cancer candidate granted FDA Priority Review

Johnson & Johnson announced that the FDA has granted Priority Review to the supplemental Biologics License Application for...

7d ago

JNJ

Johnson & Johnson sees Firefly, Sail Biomedicines dilute FY27 EPS by $1.36

The company states: “The combination of these two transactions is also expected to reduce the Company’s 2027 Adjusted...

8d ago

JNJ

JNJ enters strategic agreement to acquire Sail Biomedicines for $2.58B

Johnson & Johnson “announced strategic agreements and collaboration with Sail Biomedicines (Sail), a biotechnology company developing in vivo...

8d ago

JNJ

Johnson & Johnson cuts FY26 EPS view to $10.86-$11.01, consensus $11.68

Prior guidance was $11.50-$11.65. On July 29, 2026, Johnson & Johnson announced the completion of the acquisition of...

8d ago

JNJ

Johnson & Johnson affirms FY26 revenue view of $100.8B-$101.4B

Cuts FY26 operating margin view to down 75bps from up 75bps vs. prior year. Published first on TheFly...

8d ago

JNJ

JNJ’s OTTAVA Robotics and Medtech Strategy Underpin Buy Rating and Unchanged $282 Price Target

Analyst Asad Haider of Goldman Sachs reiterated a Buy rating on Johnson & Johnson, retaining the price target...

2d ago

JNJ

JNJ FAQ

What was Johnson & Johnson’s price range in the past 12 months?

Johnson & Johnson lowest stock price was $169.68 and its highest was $274.90 in the past 12 months.

What is Johnson & Johnson’s market cap?

Johnson & Johnson’s market cap is $617.78B.

When is Johnson & Johnson’s upcoming earnings report date?

Johnson & Johnson’s upcoming earnings report date is Oct 20, 2026 which is in 75 days.

How were Johnson & Johnson’s earnings last quarter?

Johnson & Johnson released its earnings results on Jul 15, 2026. The company reported $2.9 earnings per share for the quarter, beating the consensus estimate of $2.855 by $0.045.

Is Johnson & Johnson overvalued?

According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Johnson & Johnson pay dividends?

Johnson & Johnson pays a Quarterly dividend of $1.34 which represents an annual dividend yield of 2.04%. See more information on Johnson & Johnson dividends here

What is Johnson & Johnson’s EPS estimate?

Johnson & Johnson’s EPS estimate is 2.9.

How many shares outstanding does Johnson & Johnson have?

Johnson & Johnson has 2,409,898,700 shares outstanding.

What happened to Johnson & Johnson’s price movement after its last earnings report?

Johnson & Johnson reported an EPS of $2.9 in its last earnings report, beating expectations of $2.855. Following the earnings report the stock price went down -2.691%.

Which hedge fund is a major shareholder of Johnson & Johnson?

Currently, no hedge funds are holding shares in JNJ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Johnson & Johnson Stock Smart Score

Outperform

Fundamentals

Return on Equity

2.04%

Trailing 12-Months

Asset Growth

3.97%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson (JNJ) Earnings & Revenues

Historic Earnings Reports

JNJ Company Deck

JNJ Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call was broadly positive: the company reported solid top‑line growth, strong performance from a broad set of Innovative Medicine launches (many products delivering high double‑digit growth), successful new product launches (ICOTYDE, INLEXZO), raised guidance for full‑year sales and EPS, and improved operating margin expectations. Headwinds exist — notably STELARA's steep decline, MedTech pressure in cardiovascular/Abiomed, regional inventory impacts (China), higher other expenses and a higher GAAP tax rate — but management characterized these as addressable and emphasized diversified, multi‑product strength, cash flow recovery, and upcoming pipeline and regulatory catalysts.View all JNJ earnings summaries

JNJ Sales Breakdown

64.12% Innovative Medicine

35.88% MedTech

JNJ Stock 12 Month Forecast

Average Price Target

$281.00

▲(6.68% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"163":"$163","306":"$306","198.75":"$198.8","234.5":"$234.5","270.25":"$270.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":305,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$305.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":281,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$281.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":255,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$255.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[163,198.75,234.5,270.25,306],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,256.35,260.0923076923077,263.8346153846154,267.5769230769231,271.3192307692308,275.0615384615385,278.80384615384617,282.54615384615386,286.28846153846155,290.03076923076924,293.7730769230769,297.5153846153846,301.2576923076923,{"y":305,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,256.35,258.24615384615385,260.1423076923077,262.03846153846155,263.9346153846154,265.83076923076925,267.7269230769231,269.62307692307695,271.5192307692308,273.4153846153846,275.3115384615385,277.2076923076923,279.1038461538462,{"y":281,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,256.35,256.24615384615385,256.1423076923077,256.03846153846155,255.9346153846154,255.83076923076925,255.7269230769231,255.62307692307692,255.51923076923077,255.41538461538462,255.31153846153848,255.2076923076923,255.10384615384615,{"y":255,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":164.189,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.121,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":183.898,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":186.685,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.254,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205.855,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":229.529,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":248.56,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":244.12,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":227.19,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":223.51,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":253.98,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":256.35,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >